Free Trial

Sarepta Therapeutics (SRPT) Stock Price, News & Analysis

Sarepta Therapeutics logo
$19.07 -0.30 (-1.55%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$19.06 -0.02 (-0.08%)
As of 08:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Sarepta Therapeutics Stock (NASDAQ:SRPT)

Key Stats

Today's Range
$18.50
$19.53
50-Day Range
$17.10
$63.66
52-Week Range
$16.88
$154.13
Volume
3.11 million shs
Average Volume
2.23 million shs
Market Capitalization
$1.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.54
Consensus Rating
Hold

Company Overview

Sarepta Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
95th Percentile Overall Score

SRPT MarketRank™: 

Sarepta Therapeutics scored higher than 95% of companies evaluated by MarketBeat, and ranked 55th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sarepta Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 12 buy ratings, 12 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Sarepta Therapeutics has been the subject of 24 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Sarepta Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Sarepta Therapeutics are expected to grow by 309.74% in the coming year, from $2.67 to $10.94 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sarepta Therapeutics is -7.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sarepta Therapeutics is -7.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sarepta Therapeutics has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Sarepta Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    10.90% of the float of Sarepta Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Sarepta Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sarepta Therapeutics has recently increased by 6.80%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Sarepta Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Sarepta Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.90% of the float of Sarepta Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Sarepta Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sarepta Therapeutics has recently increased by 6.80%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Sarepta Therapeutics has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 41 news articles for Sarepta Therapeutics this week, compared to 16 articles on an average week.
  • Search Interest

    Only 68 people have searched for SRPT on MarketBeat in the last 30 days. This is a decrease of -1% compared to the previous 30 days.
  • MarketBeat Follows

    16 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sarepta Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.70% of the stock of Sarepta Therapeutics is held by insiders.

  • Percentage Held by Institutions

    86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Sarepta Therapeutics' insider trading history.
Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Stock News Headlines

Photo of Solid Biosciences logo and genes
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences (SRPT)
After a second patient passed away, Sarepta Therapeutics crashed. Solid Biosciences rose over 10% in response. Wall Street sees big upside in both names.
[No Brainer Gold Play]: “Show me a better investment.”
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
See More Headlines

SRPT Stock Analysis - Frequently Asked Questions

Sarepta Therapeutics' stock was trading at $121.59 at the start of the year. Since then, SRPT stock has decreased by 84.3% and is now trading at $19.07.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) issued its quarterly earnings results on Tuesday, May, 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.20 by $5.62. The company's quarterly revenue was up 80.2% compared to the same quarter last year.
Read the conference call transcript
.

Sarepta Therapeutics subsidiaries include these companies: Myonexus Therapeutics, Eisai, Sarepta Securities Corp., Sarepta Therapeutics Three LLC, and ST International Holdings Two Inc..

Sarepta Therapeutics' top institutional investors include Sovran Advisors LLC (0.06%). Insiders that own company stock include Douglas S Ingram, Michael Andrew Chambers, Richard Barry, Ian Michael Estepan, Claude Nicaise, Hans Lennart Rudolf Wigzell, Bilal Arif, Dallan Murray, Ryan Edward Brown, Stephen Mayo and Kathryn Jean Boor.
View institutional ownership trends
.

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sarepta Therapeutics investors own include Zomedica (ZOM), NVIDIA (NVDA), Humana (HUM), American Water Works (AWK), Meta Platforms (META), Voyager Therapeutics (VYGR) and Waste Connections (WCN).

Company Calendar

Last Earnings
5/06/2025
Today
7/11/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SRPT
Previous Symbol
NASDAQ:AVII
CIK
873303
Employees
1,372
Year Founded
1980

Price Target and Rating

High Price Target
$160.00
Low Price Target
$24.00
Potential Upside/Downside
+207.0%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
25 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.69)
Trailing P/E Ratio
N/A
Forward P/E Ratio
7.14
P/E Growth
N/A
Net Income
$235.24 million
Net Margins
-11.12%
Pretax Margin
-7.35%
Return on Equity
-14.88%
Return on Assets
-5.12%

Debt

Debt-to-Equity Ratio
1.00
Current Ratio
4.02
Quick Ratio
2.46

Sales & Book Value

Annual Sales
$2.23 billion
Price / Sales
0.84
Cash Flow
$2.40 per share
Price / Cash Flow
7.95
Book Value
$15.99 per share
Price / Book
1.19

Miscellaneous

Outstanding Shares
98,277,000
Free Float
90,710,000
Market Cap
$1.87 billion
Optionable
Optionable
Beta
0.45

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:SRPT) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners